US Market Report for Ulcerative Colitis Immunology Drugs 2018 - MedCore

Tuesday, November 7, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 6, 2017 /PRNewswire/ --

General Report Contents- Market Analyses include: Unit Sales, ASPs,

Market Value & Growth TrendsRead the full report: https://www.reportlinker.com/p05175236- Market Drivers & Limiters for each chapter segment- Competitive Analysis for each chapter segment- Section on recent mergers & acquisitionsColonoscopy
procedures, blood tests and stool samples are commonly used in diagnosis of ulcerative colitis as well as medical imaging and description of the disease and symptoms. These tests can also help to rule out other disease that may occur with similar symptoms (Crohn's disease, diverticulitis).Treatment options include medication to control the symptoms, lifestyle and dietary changes, reduction of stress, moderate activity and exercise. A mild form of UC requires over-the-counter medicines for diarrhea (such as Imodium). More severe form of the disease requires prescription medicines, such as aminosalicylates, steroid medicines or other medicines that reduce the body's immune response.Acute treatment involves antibiotics, anti-inflammatory drugs and corticosteroids. Prolonged use of corticosteroids has significant side-effects; as a result, they are, in general, not used for long-term treatment. Aminosalicylates are often more effective in ulcerative colitis than in Crohn's disease. This treatment showed positive results in mild to moderate UC.Another treatment option includes biologic agents, including an anti-tumor necrotizing factor-? (anti-TNF-?) agent. Currently available biologic agents include HUMIRA® (adalimumab) and its biosimilars Amjevita™ and Imraldi®, REMICADE® (infliximab) and its biosimilar Flixabi®, SIMPONI® (golimumab), Renflexis™ (Infliximab-abda) and ENTYVIO® (vedolizumab).AbstractUlcerative colitis (UC) is a type of an inflammatory bowel disease (IBD). Ulcerative colitis and Crohn's disease are the most common type of the IBD. Both diseases affect the GI system with similar symptoms while the course of the diseases and treatments may be different. UC usually affects large intestine (rectum and colon), while CD can affect any part of the GI tract.UC causes an inflammation and cores (ulcers) in the colon and usually affects the sigmoid colon (lower section of a large intestine) and rectum. The disease may affect people at any age, but usually it is diagnosed in people before the age of 30. UC can be controlled with medication and in severe cases can even be treated by a surgical removal of the entire large intestine.Scope2014-2024Read the full report: https://www.reportlinker.com/p05175236 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. https://www.reportlinker.com __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/us-market-report-for-ulcerative-colitis-immunology-drugs-2018---medcore-300550606.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store